-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Clinically, about half of testicular tumors are seminoma
.
The survival rate after orchiectomy for stage I seminoma is almost 100%
.
The survival rate after orchiectomy for stage I seminoma is almost 100%
The TRISST trial was a noninferiority, phase 3 factorial trial designed to assess whether the use of magnetic resonance imaging (MRI) or reduced frequency of scans did not increase the rate of late recurrence
.
6-year late recurrence rate on MRI vs CT scan
6-year late recurrence rate on MRI vs CT scanBetween 2008 and 2014, a total of 669 patients were recruited, the mean tumor size was 2.
9 cm, and 358 (54%) were low-risk (<4 cm, without rete testis involvement)
.
After a median follow-up of 72 months, 82 (12%) patients relapsed
.
669
6-year late recurrence rate with 3 vs 7 scans
6-year late recurrence rate with 3 vs 7 scansIn addition, the analysis showed that MRI was not inferior to CT ; MRI detected fewer recurrences (2 [0.
6%] vs 8 [2.
The results of the analysis showed that the performance of MRI was not inferior to that of CT.
MRI can reduce the amount of radiation; and reducing the number of scans has no adverse effect on long-term prognosis
Original source:
Original source:Johnathan K.
Joffe, et al.
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
J Clin Oncol.
March 15, 2022.
https://ascopubs.
leave a message here